Építés alatt – nem éles oldal
Belépés
Befejeződött2. fázis

Low Nicotine Content Cigarettes in Vulnerable Populations: Affective Disorders

A legfontosabb adatok

Ki végzi
Brown University
Hol
Burlington és Providence (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
2. fázis
Résztvevők
326 fő vett részt
Kezdés
2020. okt. 18.
Befejezés
2023. nov. 27.
A vizsgálat típusa
Beavatkozással járó, 4 csoport
A vizsgált kezelések
  • Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)
  • E-Cigarettes
A regiszteradat frissítve
2025. április 1.

Ki vehet részt

Életkor
18 év – 70 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 5 feltétel megnézéseKevesebb

Ki vehet részt

  • Between 21 years and 70 years old
  • Must have current diagnosis of an Affective Disorder

Ki nem vehet részt

  • Being without an Affective Disorder
  • Younger than 21 years old
  • Older than 70 years old

Helyszínek itt: Egyesült Államok

  • University of VermontBurlington, Egyesült Államok
  • Brown UniversityProvidence, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

While the prevalence of smoking in the United States general population has declined over the past 50 years, there has been little to no decline among people with mental health conditions. Affective Disorders (ADs) are the most common mental health conditions in the US, and over 40% of people with ADs are current smokers. A national policy of reducing the nicotine content of cigarettes has the potential to reduce tobacco use, dependence, and related adverse health outcomes. Controlled trials in psychiatrically-stable smokers have shown that reducing the nicotine content in cigarettes can reduce cigarettes per day (CPD), dependence and tobacco toxicant exposure, with few adverse consequences.

A teljes eredeti leírásKevesebb

The goal of the proposed trial is to experimentally model whether increasing the availability and appeal of an alternative, non-combusted source of nicotine (e-cigarettes) moderates the effect of altering the nicotine in cigarettes in smokers with ADs. Additionally, investigators will test whether allowing participants to personalize the flavor of the e-liquid alters any moderating effects their availability may have on tobacco cigarette smoking.

Daily smokers with current ADs will be recruited at Brown University and the University of Vermont.

Investigators will study two research cigarettes referred to here as Research Cigarette 1 (RC1) and Research Cigarette 2 (RC2). One of these cigarettes will be a normal nicotine content cigarette and the other will be a reduced nicotine content cigarette. Investigators will study two e-cigarette conditions referred to here as E-Cigarette Condition 1 (EC1) and E-Cigarette Condition 2 (EC2). Both e-cigarette conditions will involve the same commercially available devices and same nicotine-containing e-liquid, but in one condition that e-liquid will be available only in tobacco flavor while in the other condition that e-liquid will be available in multiple flavors from which participants can choose based on personal taste preference. Participants will be assigned to one of the following four study conditions: (1) RC1 only; (2) RC2 only; (3) RC2 + EC1; (4) RC2 + EC2.

Participants will be asked to use only their assigned study products for 16 weeks. Outcome measures include total CPD, cigarette demand assessed by behavioral economics-based purchase tasks, craving, withdrawal, psychiatric symptoms, breath carbon monoxide (CO), biomarkers of tobacco toxicant exposure, brain function and structure, and airway inflammation (fractional nitric oxide concentration in exhaled breath [FeNO]).

A vizsgálat 4 csoportja

  • RC 1 onlyA vizsgált kezelés

    Research Cigarettes #1

    Kezelés: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)

  • RC 2 onlyA vizsgált kezelés

    Research Cigarettes #2

    Kezelés: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g)

  • RC 2 + EC 1A vizsgált kezelés

    Research Cigarettes #2 plus E-cigarettes #1 (participants receive tobacco flavor only)

    Kezelés: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g) és E-Cigarettes

  • RC 2 + EC 2A vizsgált kezelés

    Research Cigarettes #2 plus E-cigarettes #2 (participants can choose among varying flavors)

    Kezelés: Either normal nicotine content cigarettes (15.8mg/g) or reduced nicotine content cigarettes (0.4mg/g) és E-Cigarettes

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Publikációk
A regiszteradat frissítve
2025. április 1.